Complarate (tocilizumab biosimilar)
/ Generium
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 31, 2025
A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=256 | Active, not recruiting | Sponsor: AO GENERIUM | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Sep 2025 | Trial primary completion date: Sep 2024 ➔ Apr 2025
Enrollment closed • Trial completion date • Trial primary completion date
July 05, 2024
A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=256 | Recruiting | Sponsor: AO GENERIUM
New P1 trial
July 01, 2024
A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=43 | Completed | Sponsor: AO GENERIUM
New P1 trial
June 26, 2024
Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
(clinicaltrials.gov)
- P3 | N=465 | Completed | Sponsor: AO GENERIUM
New P3 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
1 to 4
Of
4
Go to page
1